STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to shrink tough liver tumors
Disease control OngoingThis early-phase trial tests whether combining regorafenib (a drug that blocks cancer cell growth) with durvalumab (an immunotherapy that helps the immune system attack cancer) can shrink tumors in people with high-risk liver cancer. The study enrolled 4 adults with liver cancer …
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Tailored radiation doses aim to shrink liver tumors
Disease control OngoingThis study tests whether giving a personalized dose of radiation directly to liver tumors can improve treatment results for people with advanced liver cancer that cannot be removed by surgery. About 42 participants will receive a customized radiation plan based on their individua…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Immunotherapy duo after radiation shows promise for inoperable liver cancer
Disease control OngoingThis early-phase study tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) after a targeted radiation procedure can help people with advanced liver cancer that cannot be surgically removed. The trial includes 25 adults whose cancer has spread within the liv…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
New combo shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis study tests a new drug called pevonedistat, given alone or with standard chemotherapy (paclitaxel and carboplatin), in people with advanced bile duct cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors. About 40 adults who hav…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 24, 2026 16:05 UTC